Masand 2009.

Study characteristics
Methods	Design: parallel Duration: 12 weeks Assessment: baseline and post‐intervention Country: USA
Participants	Pain condition: IBS Population: adults aged 18‐75 with IBS Minimum pain intensity: no Inclusion criteria Confirmed diagnosis of IBS by use of Rome II diagnostic criteria for over 1 year Exclusion criteria Physical and mental health comorbidies Total participants randomised: 72 Age in years (mean): 49.0 Gender: 63/72 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 36 Inert Dosing matched to antidepressant arm Paroxetine 12.5‐50 mg n = 36 SSRI Forced titration to maximum tolerated dose
Outcomes	SAEs Withdrawal
Missing data methods	ITT with LOCF
Funding source	Pharmaceutical: This study was supported by a collaborative research grant from GlaxoSmithKline.
Conflicts of interest	Dr Masand is a consultant for Bristol‐Myers Squibb Company, Cephalon, Inc., Eli Lilly and Company, Forest Pharmaceutical Laboratories Inc., GlaxoSmithKline, Janssen Pharmaceutica, Jazz Pharmaceuticals, Organon, Inc., Pfizer Inc., U.S. Pharmaceuticals Group., Targacept Inc., and Wyeth Pharmaceuticals. He is on the speaker's bureau of Astra‐Zeneca, Bristol‐Myers Squibb Company, Forest Pharmaceutical Laboratories, Inc., GlaxoSmithKline, Janssen Pharmaceutica, Pfizer Inc., U.S. Pharmaceuticals Group., and Wyeth Pharmaceuticals. He has received research support from AstraZeneca Pharmaceuticals, Bristol‐Myers Squibb Company, Cephalon, Inc.., Eli Lilly and Company, Forest Pharmaceutical Laboratories Inc., GlaxoSmithKline, Ortho McNeil Pharmaceutical, Inc., Janssen Pharmaceutica, and Wyeth Pharmaceuticals, and is an employee of i3CME. Dr Patkar is a consultant for Bristol‐Myers Squibb Company, GlaxoSmithKline, and Reckitt Benckiser; he is on the speaker's bureau of Bristol‐Myers Squibb Company, GlaxoSmithKline, and Reckitt Benckiser, and has received research support from National Institutes of Health, AstraZeneca Pharmaceuticals, Bristol‐Myers Squibb Company, Forest Pharmaceuticals, Inc., GlaxoSmithKline, Janssen Pharmaceutica, McNeil Consumer and Specialty Inc., Organon, Inc., Jazz Pharmaceuticals, and Pfizer Inc., U.S. Pharmaceuticals Group. Dr Pae has received research support from GlaxoSmithKline. Mr. Krulewicz is an employee of GlaxoSmithKline and owns common stock in the company.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation methods not described
Allocation concealment (selection bias)	Low risk	Participants were allocated using an Interactive Voice Response System
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind, matching drug appearance and identical dosing schedules
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Self‐reported outcomes from blinded participants
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT with LOCF Attrition Total: 14/72 (19.4%) Placebo: 8/36 (22.2%) Paroxetine 12.5‐50 mg: 6/36 (16.7%)
Selective reporting (reporting bias)	High risk	Trial registry lists quality of life and IBS symptoms as outcomes but these are NR. Beck Depression Index and Beck Anxiety Index are NR for all participants, divided into samples with or without history of anxiety and depression.
Other bias	Low risk	No other sources of bias were identified